Cue Biopharma, Inc. cash flow to debt ratio of -516.73% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cue Biopharma, Inc.'s free cash flow has increased -39.93% from $-36.40M last year to $-21.86M, signaling increasing performance

Cue Biopharma, Inc.'s debt to equity ratio is 0.16, which means that the company's assets are healthy financed, signaling financial stability.

Cue Biopharma, Inc.'s debt has decreased relative to shareholder equity from 0.51 last year to 0.16 today, signaling strengthened financials

Cue Biopharma, Inc. has a net cash position, so leverage is healthy.

Cue Biopharma, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cue Biopharma, Inc.'s profit margin has increased (-86.38%) in the last year from -437.97% to -59.65%, signaling increasing performance

Cue Biopharma, Inc.'s short-term assets of $36.98M exceed its short-term liabilities of $13.49M

Cue Biopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cue Biopharma, Inc.'s return on equity of -98.30%, is lower than 15.00%, indicating bad performance

Cue Biopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cue Biopharma, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Cue Biopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cue Biopharma, Inc. has negative free cash flow, indicating cash burn

Cue Biopharma, Inc.'s yearly earnings has increased -34.60% since last year from $-40.67M to $-26.60M, signaling increasing performance

Cue Biopharma, Inc.'s yearly revenue has increased 195.75% since last year from $9.29M to $27.47M, signaling increasing performance

ROIC -78.19% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cue Biopharma, Inc.'s 3-year revenue CAGR of 180.46% is positive, indicating growing revenue over the past 3 years

Cue Biopharma, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Cue Biopharma, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Cue Biopharma, Inc. has insufficient data to evaluate this check.

Cue Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cue Biopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cue Biopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cue Biopharma, Inc. is overvalued relative to its fair value price of -752.29 based on Earnings Fair Value model

Cue Biopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cue Biopharma, Inc. has a price-to-book ratio of 5.81x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Cue Biopharma, Inc. has a price-to-sales ratio of 3.83x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue